Transfer of this miRNA in exosomes to sensitive cells activates the mammalian target of rapamycin (mTOR) signaling pathway conferring resistance to gemcitabine-sensitive pancreatic cancer cells (122). Here, MTOR is linked to pancreatic neoplasm.